Abstract #1497

Detecting cancer immunotherapy response in ccRCC patients from 1H MRS of plasma

Raj Kumar Sharma¹, Michael T. McMahon², Meiyappan Solaiyappan¹, Yasser Ged³, and Zaver M Bhujwalla¹

¹Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, JOHNS HOPKINS UNIVERSITY, SCHOOL OF MEDICINE, BALTIMORE, MD, United States, ²F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, JOHNS HOPKINS UNIVERSITY, SCHOOL OF MEDICINE, Baltimore, MD, United States, ³Genitourinary Oncology, Sidney Kimmel Comprehensive Cancer Center, JOHNS HOPKINS UNIVERSITY, SCHOOL OF MEDICINE, Baltimore, MD, United States

Synopsis

Keywords: Cancer, Metabolism, Clear Cell Renal Cell Carcinoma , Cancer , 1H MR metabolomicsA minimally invasive, blood-based assay to predict and detect response to immune-checkpoint inhibitors (ICIs) would be of significant importance. 1H MRS of plasma samples provides a robust reproducible assay that require minimal sample preparation, and convenience of sample storage. Here we evaluated changes in plasma metabolites of clear cell renal cell carcinoma (ccRCC) patients receiving ICIs using 1H MRS. We identified a significant increase of acetate, formate, glutamine, glycine, myoinositol, and lactate following ICI that may reflect response.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.